Researchers consider R/R ALL drugs in the first-line settingOctober 17, 2018Immuno-oncologyHematologic Malignancies
Will quad therapy become the new standard in myeloma?October 2, 2018Multiple MyelomaHematologic Malignancies
Real-world clues for optimal sequencing of CLL novel agentsSeptember 25, 2018Hematologic Malignancies
STORM trial shows response in penta-refractory myelomaSeptember 16, 2018Multiple MyelomaHematologic MalignanciesOncology
Occurrence of Skeletal-Related Events in Multiple Myeloma and Prostate Cancer Patients Receiving Standard Versus Extended-Interval Zoledronic Acid September 12, 2018Multiple MyelomaProstate CancerHematologic Malignancies
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patientsSeptember 6, 2018Hematologic Malignancies
Fracture risk linked to mortality in women with myelomaAugust 29, 2018Multiple MyelomaHematologic Malignancies
Immunotherapies shape the treatment landscape for hematologic malignanciesAugust 15, 2018OncologyHematologic Malignancies
FDA warns against azithromycin in blood or lymph node cancersAugust 3, 2018Mixed TopicsInfectious DiseasesHematologic Malignancies
Do Erythropoiesis-Stimulating Agents Have a Risk Evaluation and Mitigation Strategy? (FULL)August 2, 2018Hematologic MalignanciesFDA Actions
